hI-con1 (ICON-1) / Endpoint Health - LARVOL DELTA

[VIRTUAL] Activity and pharmacokinetics of ICON-4, a New Antibody Targeting Tissue Factor (ARVO 2021) - "ICON-4 is a potent TF inhibitor with optimized properties well suited and formulated for IVT administration. ICON-4 high affinity is expected to result in more complete TF inhibition with potential for higher efficacy and/or longer duration of action without enhanced risks of bleeding compared to ICON-1."

PK/PD data • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • CXCL8

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - P2; N=15; Terminated; Sponsor: Iconic Therapeutics, Inc.; Completed ➔ Terminated; Business Reasons

Clinical • Trial termination • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - P2; N=15; Completed; Sponsor: Iconic Therapeutics, Inc.; Active, not recruiting ➔ Completed

Trial completion • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Phase 1, Open-Label, Dose-Escalation Trial to Investigate Safety and Tolerability of Single Intravitreous Injections of ICON-1 Targeting Tissue Factor in Wet AMD. (PubMed, Ophthalmic Surg Lasers Imaging Retina) - "Intravitreous administration of ICON-1 in single doses up to 300 μg in eyes with neovascular AMD was safe and well-tolerated."

Clinical • Journal • P1 data • Age-related Macular Degeneration • Biosimilar • Complement-mediated Rare Disorders • Gene Therapies • Genetic Disorders • Ophthalmology • Rare Diseases